News | December 15, 2022
Briefs: Jubilant Pharmova and Apollo Hospitals Enterprise
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The current ruling will assure the safety of the use of Ranitidine for Indian patients
This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Subscribe To Our Newsletter & Stay Updated
